Literature DB >> 32561530

Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis.

Emanuele Giurisato1,2, Silvia Lonardi3, Brian Telfer4, Sarah Lussoso5, Blanca Risa-Ebrí2, Jingwei Zhang2, Ilaria Russo6,7, Jinhua Wang8,9, Annalisa Santucci5, Katherine G Finegan4, Nathanael S Gray8,9, William Vermi3,10, Cathy Tournier11.   

Abstract

The presence of immunosuppressive macrophages that become activated in the tumor microenvironment constitutes a major factor responsible for tumor growth and malignancy. In line with this knowledge, we report here that macrophage proliferation is a significant feature of advanced stages of cancer. Moreover, we have found that a high proportion of proliferating macrophages in human tumors express ERK5. ERK5 was required for supporting the proliferation of macrophages in tumor grafts in mice. Furthermore, myeloid ERK5 deficiency negatively impacted the proliferation of both resident and infiltrated macrophages in metastatic lung nodules. ERK5 maintained the capacity of macrophages to proliferate by suppressing p21 expression to halt their differentiation program. Collectively, these data provide insight into the mechanism underpinning macrophage proliferation to support malignant tumor development, thereby strengthening the value of ERK5-targeted therapies to restore antitumor immunity through the blockade of protumorigenic macrophage activation. SIGNIFICANCE: These findings offer a new rationale for anti-ERK5 therapy to improve cancer patient outcomes by blocking the proliferative activity of tumor macrophages. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32561530      PMCID: PMC7611207          DOI: 10.1158/0008-5472.CAN-19-2416

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases.

Authors:  J M English; G Pearson; R Baer; M H Cobb
Journal:  J Biol Chem       Date:  1998-02-13       Impact factor: 5.157

2.  Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung.

Authors:  Alexander V Misharin; Luisa Morales-Nebreda; Gökhan M Mutlu; G R Scott Budinger; Harris Perlman
Journal:  Am J Respir Cell Mol Biol       Date:  2013-10       Impact factor: 6.914

Review 3.  ERK5: structure, regulation and function.

Authors:  Gopika N Nithianandarajah-Jones; Bettina Wilm; Christopher E P Goldring; Jürgen Müller; Michael J Cross
Journal:  Cell Signal       Date:  2012-07-16       Impact factor: 4.315

4.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.

Authors:  Kiavash Movahedi; Damya Laoui; Conny Gysemans; Martijn Baeten; Geert Stangé; Jan Van den Bossche; Matthias Mack; Daniel Pipeleers; Peter In't Veld; Patrick De Baetselier; Jo A Van Ginderachter
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

5.  Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies.

Authors:  Robert L Bowman; Florian Klemm; Leila Akkari; Stephanie M Pyonteck; Lisa Sevenich; Daniela F Quail; Surajit Dhara; Kenishana Simpson; Eric E Gardner; Christine A Iacobuzio-Donahue; Cameron W Brennan; Viviane Tabar; Philip H Gutin; Johanna A Joyce
Journal:  Cell Rep       Date:  2016-11-10       Impact factor: 9.423

Review 6.  Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice.

Authors:  Masaaki Hayashi; Jiing-Dwan Lee
Journal:  J Mol Med (Berl)       Date:  2004-10-28       Impact factor: 4.599

7.  CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.

Authors:  Bin-Zhi Qian; Jiufeng Li; Hui Zhang; Takanori Kitamura; Jinghang Zhang; Liam R Campion; Elizabeth A Kaiser; Linda A Snyder; Jeffrey W Pollard
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

8.  The cellular and molecular origin of tumor-associated macrophages.

Authors:  Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li
Journal:  Science       Date:  2014-05-08       Impact factor: 47.728

9.  Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer.

Authors:  Min Liu; Zan Tong; Chuanlin Ding; Fengling Luo; Shouzhen Wu; Caijun Wu; Sabrin Albeituni; Liqing He; Xiaoling Hu; David Tieri; Eric C Rouchka; Michito Hamada; Satoru Takahashi; Andrew A Gibb; Goetz Kloecker; Huang-Ge Zhang; Michael Bousamra; Bradford G Hill; Xiang Zhang; Jun Yan
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 10.  Targeting macrophages: therapeutic approaches in cancer.

Authors:  Luca Cassetta; Jeffrey W Pollard
Journal:  Nat Rev Drug Discov       Date:  2018-10-26       Impact factor: 84.694

View more
  10 in total

1.  Immunohistochemical Detection of SARS-CoV-2 Antigens by Single and Multiple Immunohistochemistry.

Authors:  Silvia Lonardi; Mattia Bugatti; Arianna Valzelli; Fabio Facchetti
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Investigating Cutaneous Squamous Cell Carcinoma in vitro and in vivo: Novel 3D Tools and Animal Models.

Authors:  Marika Quadri; Alessandra Marconi; Simran K Sandhu; Alexi Kiss; Tatiana Efimova; Elisabetta Palazzo
Journal:  Front Med (Lausanne)       Date:  2022-05-09

Review 3.  Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy.

Authors:  Francesca Cersosimo; Silvia Lonardi; Giulia Bernardini; Brian Telfer; Giulio Eugenio Mandelli; Annalisa Santucci; William Vermi; Emanuele Giurisato
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

Review 4.  Research trends in pharmacological modulation of tumor-associated macrophages.

Authors:  Neng Wang; Shengqi Wang; Xuan Wang; Yifeng Zheng; Bowen Yang; Juping Zhang; Bo Pan; Jianli Gao; Zhiyu Wang
Journal:  Clin Transl Med       Date:  2021-01

5.  Tumor-associated neutrophils (TANs) in human carcinoma-draining lymph nodes: a novel TAN compartment.

Authors:  Silvia Lonardi; Francesco Missale; Stefano Calza; Mattia Bugatti; Raffaella Vescovi; Bresciani Debora; Ravindra Uppaluri; Ann Marie Egloff; Davide Mattavelli; Davide Lombardi; Luisa Benerini Gatta; Olivia Marini; Nicola Tamassia; Elisa Gardiman; Marco A Cassatella; Patrizia Scapini; Piero Nicolai; William Vermi
Journal:  Clin Transl Immunology       Date:  2021-02-16

6.  Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.

Authors:  Won Jin Ho; Qingfeng Zhu; Jennifer Durham; Aleksandra Popovic; Stephanie Xavier; James Leatherman; Aditya Mohan; Guanglan Mo; Shu Zhang; Nicole Gross; Soren Charmsaz; Dongxia Lin; Derek Quong; Brad Wilt; Ihab R Kamel; Matthew Weiss; Benjamin Philosophe; Richard Burkhart; William R Burns; Chris Shubert; Aslam Ejaz; Jin He; Atul Deshpande; Ludmila Danilova; Genevieve Stein-O'Brien; Elizabeth A Sugar; Daniel A Laheru; Robert A Anders; Elana J Fertig; Elizabeth M Jaffee; Mark Yarchoan
Journal:  Nat Cancer       Date:  2021-07-29

7.  MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.

Authors:  Jin Wang; Lingxia Liu
Journal:  J Ovarian Res       Date:  2021-11-19       Impact factor: 4.234

8.  Ulinastatin promotes macrophage efferocytosis and ameliorates lung inflammation via the ERK5/Mer signaling pathway.

Authors:  Jinju Li; Rongge Shao; Qiuwen Xie; Ke Qin; ShaoPeng Ming; Yongguo Xie; XueKe Du
Journal:  FEBS Open Bio       Date:  2022-07-11       Impact factor: 2.792

Review 9.  ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?

Authors:  Simon J Cook; Pamela A Lochhead
Journal:  Front Cell Dev Biol       Date:  2022-07-12

Review 10.  Clinical Significance and Regulation of ERK5 Expression and Function in Cancer.

Authors:  Matilde Monti; Jacopo Celli; Francesco Missale; Francesca Cersosimo; Mariapia Russo; Elisa Belloni; Anna Di Matteo; Silvia Lonardi; William Vermi; Claudia Ghigna; Emanuele Giurisato
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.